Table 4. Results of logistic regression analysis evaluating characteristics of participants in the test, treat, and prevent HIV program with prevalent HIV infection who chose to start antiretroviral therapy (ART), Thailand, 2015–2016.
| Characteristics (data available on 302 participants) | Started ART | Bivariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|
| Odds Ratio (95% CI) | P-value | Odds Ratio (95% CI) | P-value | ||
| Site enrolleda | |||||
| Khon Kaen Hospital (n = 29) | 22 (75.9) | 1.0 | 1.0 | ||
| Lerdsin Hospital (n = 55) | 54 (98.2) | 17.2 (2.0–148.0) | 0.01 | 13.9 (1.5–129.8) | 0.02 |
| Srinagarind Hospital (n = 38) | 29 (76.3) | 1.0 (0.3–3.2) | 0.97 | 1.3 (0.4–4.6) | 0.64 |
| Thammasat Hospital (n = 62) | 43 (69.4) | 0.7 (0.3–2.0) | 0.52 | 1.0 (0.3–3.1) | 0.99 |
| Udon Thani Hospital (n = 118) | 112 (94.9) | 5.9 (1.8–19.4) | 0.003 | 7.6 (2.1–27.3) | 0.002 |
| Recruitment method | |||||
| Peer-driven intervention (n = 38) | 31 (81.6) | 1.0 | |||
| Walked in to clinic (n = 264) | 229 (86.7) | 2.1 (0.7–7.0) | 0.20 | Not included | |
| Self-identified as | |||||
| Transgender woman (n = 39) | 31 (79.5) | 1.0 | |||
| Man who has sex with men (n = 263) | 229 (87.1) | 1.3 (0.5–3.2) | 0.60 | Not included | |
| Age at enrollment | |||||
| 18–21 years (n = 90) | 74 (82.2) | 1.0 | |||
| ≥22 years (n = 212) | 186 (87.7) | 1.4 (0.7–2.8) | 0.41 | Not included | |
| Education | |||||
| Secondary or less (n = 168) | 138 (82.1) | 1.0 | |||
| More than secondary (n = 134) | 122 (91.0) | 1.5 (0.7–3.3) | 0.26 | Not included | |
| Income per month | |||||
| <5000 baht (n = 69) | 55 (79.7) | 1.0 | 1.0 | ||
| 5000–10,000 baht (n = 110) | 90 (81.8) | 1.8 (0.8–4.3) | 0.18 | 1.2 (0.5–3.1) | 0.68 |
| >10,000 bath (n = 123) | 115 (93.5) | 4.6 (1.7–12.8) | 0.003 | 3.4 (1.1–10.4) | 0.03 |
| Know a person living with HIV | |||||
| No (n = 206) | 173 (84.0) | 1.0 | 1.0 | ||
| Yes (n = 96) | 87 (90.6) | 2.0 (0.9–4.5) | 0.10 | 2.0 (0.8–5.2) | 0.14 |
| Age at first sex (data available on 301 participants) | |||||
| ≤13 years (n = 42) | 31 (73.8) | 1.0 | 1.0 | ||
| 14–16 years (n = 88) | 81 (92.1) | 3.3 (1.1–9.8) | 0.03 | 3.4 (1.0–11.4) | 0.05 |
| >16 years (n = 171) | 147 (86.0) | 1.7 (0.7–4.1) | 0.23 | 1.5 (0.6–3.9) | 0.42 |
| In the 6 months before enrollment | |||||
| Sexual activity (data available on 294 participants) | |||||
| Had receptive anal intercourse | |||||
| No (n = 60) | 51 (85.0) | 1.0 | |||
| Yes (n = 234) | 203 (86.8) | 1.3 (0.5–3.0) | 0.59 | Not included | |
| Had insertive anal intercourse | |||||
| No (n = 122) | 105 (86.1) | 1.0 | |||
| Yes (n = 172) | 149 (86.6) | 0.9 (0.5–1.9) | 0.89 | Not included | |
| Had sex with a casual partner/s | |||||
| No (n = 97) | 83 (85.6) | 1.0 | |||
| Yes (n = 197) | 171 (86.8) | 1.2 (0.6–2.5) | 0.64 | Not included | |
| Had sex with sex worker/s | |||||
| No (n = 268) | 235 (87.7) | 1.0 | 1.0 | ||
| Yes (n = 26) | 19 (73.1) | 0.4 (0.2–1.2) | 0.12 | 0.3 (0.09–1.2) | 0.09 |
| Was paid or received gifts for sex | |||||
| No (n = 246) | 217 (88.2) | 1.0 | 1.0 | ||
| Yes (n = 48) | 37 (77.1) | 0.5 (0.2–1.1) | 0.08 | 0.9 (0.3–2.7) | 0.92 |
| Drug use (data available on 301 participants) | |||||
| Injected drugs | |||||
| No (n = 294) | 254 (86.4) | 1.0 | 1.0 | ||
| Yes (n = 7) | 5 (71.4) | 0.2 (0.03–1.5) | 0.11 | 0.2 (0.02–1.5) | 0.12 |
| Used drugs (not injected)b | |||||
| No (n = 265) | 230 (86.8) | 1.0 | |||
| Yes (n = 36) | 29 (80.6) | 0.5 (0.2–1.4) | 0.17 | Not included | |
| Received information about antiretroviral medicines in the past (data available on 302 participants) | |||||
| No (n = 204) | 171 (83.8) | 1.0 | |||
| Yes (n = 98) | 89 (90.8) | 1.8 (0.9–4.1) | 0.17 | Not included | |
| Do you have concerns about antiretroviral medicines | |||||
| No (n = 50) | 40 (80.0) | 1.0 | |||
| Yes (n = 252) | 220 (87.3) | 1.8 (0.8–4.3) | 0.17 | Not included | |
| Concerned about anemia | |||||
| No (n = 270) | 233 (86.3) | 1.0 | |||
| Yes (n = 32) | 27 (84.4) | 1.0 (0.3–2.8) | 0.94 | Not included | |
| Concerned about cost of medicine | |||||
| No (n = 190) | 164 (85.7) | 1.0 | |||
| Yes (n = 112) | 96 (85.7) | 1.2 (0.6–2.4) | 0.70 | Not included | |
| Concerned about kidney problems | |||||
| No (n = 197) | 166 (84.3) | 1.0 | |||
| Yes (n = 105) | 94 (89.5) | 1.5 (0.7–3.4) | 0.27 | Not included | |
| Concerned about lipodystrophy | |||||
| No (n = 251) | 215 (85.7) | 1.0 | |||
| Yes (n = 51) | 45 (88.2) | 1.3 (0.5–3.5) | 0.58 | Not included | |
| Concerned about liver problems | |||||
| No (n = 213) | 181 (85.0) | 1.0 | |||
| Yes (n = 89) | 79 (88.8) | 1.3 (0.6–3.0) | 0.47 | Not included | |
| Concerned about rash | |||||
| No (n = 221) | 186 (84.2) | 1.0 | |||
| Yes (n = 81) | 74 (91.4) | 1.5 (0.6–3.6) | 0.40 | Not included | |
| Concerned about taking medicine every day | |||||
| No (n = 178) | 153 (86.0) | 1.0 | |||
| Yes (n = 124) | 107 (86.3) | 0.9 (0.4–1.8) | 0.69 | Not included | |
| Concerned about what my family with think | |||||
| No (n = 173) | 149 (86.1) | 1.0 | |||
| Yes (n = 129) | 111 (86.1) | 0.9 (0.4–1.8) | 0.70 | Not included | |
| Concerned about what my friends with think | |||||
| No (n = 192) | 165 (85.9) | 1.0 | |||
| Yes (n = 110) | 95 (86.4) | 1.0 (0.5–2.1) | 0.98 | Not included | |
| Know that taking antiretroviral medicine will decrease the risk a person who is infected will give HIV to a sexual partner | |||||
| No (n = 102) | 89 (87.3) | 1.0 | |||
| Yes (n = 200) | 171 (85.5) | 0.7 (0.3–1.6) | 0.43 | Not included | |
CI, confidence interval.
aWe included the site of enrollment in all models to control for clustering by site.
bFor example: alcohol, barbiturates, cocaine, heroin, ketamine, marijuana, methamphetamine, 3,4-methylenedioxy-methamphetamine (ecstasy), nitrites (poppers).